The Pharmacy Times® Retail Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to retail, community, and independent pharmacists.
April 30th 2025
Biomarker testing transforms non-small cell lung cancer treatment, enhancing outcomes through targeted therapies and next-generation sequencing for better patient care.
Pharmacists: Partner with Physicians on Chronic Care to Better Manage Patients
October 8th 2018It is important for pharmacists to position themselves as the health experts that can help patients with chronic conditions, and as the experts on the Medicare payment codes that can benefit both physician and pharmacist.
Read More
Independent Pharmacists: Separate Yourself From the Competition
October 7th 2018Offering immunizations (and making sure to carefully assess immunizations are up to date), medication therapy management (MTM), medication synchrnonization, and point of care testing are all ways, Kneeland explained, that pharmacists can carve out a niche for themselves.
Read More
Pharmacy Times and Parata Systems Celebrate 2018 Next-Generation Pharmacist Winners
October 7th 2018Pharmacy Times® and Parata Systems named the winners of the 2018 Next-Generation Pharmacist® Awards yesterday at a ceremony held concurrently with the 2018 NCPA Annual Meeting in Boston, Massachusetts.
Read More
FDA Approves Second Drug Treatment for Polyneuropathy
October 6th 2018The FDA has approved Akcea Therapeutics' inotersen (Tegsedi), an antisense oligonucleotide that inhibits the production of the transthyretin protein (amyloid), for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Read More
Officials with NCPA Applaud Opioid Relief Package, Which President Expected to Sign
October 6th 2018HR 6—which was passed in the Senate on Wednesday and in the House of Representatives last week—instructs the Secretary of Health and Human Services to establish a technical expert panel to review quality measures regarding opioids and opioid use disorders.
Read More
FDA Approves Prophylactic Treatment for Individuals With Hemophilia A
October 4th 2018Officials with the FDA have approved emicizumab-kxwh (Hemlibra, Genentech) for routine prophylaxis to prevent or reduce frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A without factor VIII inhibitors.
Read More